Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul;10(7):553-562.
doi: 10.1177/1756283X17705775. Epub 2017 Apr 26.

The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency

Angelika L Erwin  1
Affiliations
Review

The role of sebelipase alfa in the treatment of lysosomal acid lipase deficiency

Angelika L Erwin. Therap Adv Gastroenterol. 2017 Jul.

Abstract

Lysosomal acid lipase deficiency (LALD) is a lysosomal storage disorder (LSD) characterized either by infantile onset with fulminant clinical course and very poor prognosis or childhood/adult-onset disease with an attenuated phenotype. The disorder is often misdiagnosed or remains undiagnosed in children and adults due to a rather unspecific clinical presentation with dyslipidemia and steatohepatitis. Until recently, no good treatment options were available for LALD. Despite supportive and symptomatic therapies, death occurred before 1 year of age in patients with infantile-onset disease and patients with childhood/adult-onset LALD suffered from significant complications, such as liver cirrhosis, requiring liver transplantation and early-onset cardiovascular disease. With the recent approval of sebelipase alfa for clinical use in infantile- as well as childhood/adult-onset LALD, a new treatment era for this disorder has begun. Sebelipase alfa is a recombinant human lysosomal acid lipase (LAL), which is administered via the intravenous route. Clinical trials have shown significant improvement of disease parameters such as liver transaminases, hepatomegaly, and dyslipidemia in childhood/adult-onset LALD patients. Treatment of infants with the severe infantile-onset form of the disease has led to improved survival beyond the age of 1 year, and also showed improvement of hepatic and gastrointestinal symptoms, as well as growth. Overall, sebelipase alfa has a favorable safety profile and promises to be a good long-term treatment option for patients with LALD, with significant reduction of disease burden and increased life expectancy.

Keywords: Wolman disease; cholesteryl ester storage disease; hyperlipidemia; lysosomal acid lipase deficiency; nonalcoholic fatty liver disease; sebelipase alfa.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Dr Erwin has served as an advisory board member for Alexion Pharmaceuticals.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Grabowski GA, Charnas L, Du H. Lysosomal acid lipase deficiencies: the Wolman disease/cholesteryl ester storage disease spectrum. In: Valle SD, Beaudet AL, Vogelstein B, et al. (eds) The online metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2012.
    1. Fredrickson DS. Newly recognized disorders of cholesterol metabolism. Ann Intern Med 1963; 58: 718.
    1. Abramov A, Schorr S, Wolman M. Generalized xanthomatosis with calcified adrenals. AMA J Dis Child 1956; 91: 282–286. - PubMed
    1. Aslanidis C, Ries S, Fehringer P, et al. Genetic and biochemical evidence that CESD and Wolman disease are distinguished by residual lysosomal acid lipase activity. Genomics 1996; 33: 85–93. - PubMed
    1. Burton BK, Deegan PB, Enns GM, et al. Clinical features of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr 2015; 61: 619–625. - PMC - PubMed

LinkOut - more resources